Exalenz Bioscience Ltd. announced consolidated earnings results for the year ended December 31, 2012. For the year, total revenues were ILS 13,572,000 compared to ILS 12,492,000 for the same period a year ago. Operating loss was ILS 25,006,000 compared to ILS 30,424,000 for the same period a year ago.

Loss was ILS 27,138,000 or ILS 0.13 per basic and diluted share compared to ILS 34,422,000 or ILS 0.26 per basic and diluted share for the same period a year ago. Net cash used in operating activities was ILS 23,105,000 compared to ILS 29,059,000 for the same period a year ago. Purchase of fixed and intangible assets was ILS 169,000 compared to ILS 203,000 for the same period a year ago.